A Phase 3 interventional study of elagolix and estradiol/norethindrone acetate (E2/NETA) in Endometriosis, sponsored by AbbVie. Terminated at 37 sites in United States. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2019-11-27.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing elagolix in Endometriosis — 2 open to participants now, 4 under way, 2 of them phase 3. elagolix · Endometriosis.
Among the 22 studies testing elagolix in Endometriosis, this one is the 21st largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 3, and was the 12th registered.
922 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →2 of the 22 studies testing elagolix in Endometriosis are open now, in 1 country. Recruiting first, the newest first:
Pak Emirates Military Hospital · Sites in Pakistan
Ages 18–45 · Women only
Colorado State University
Ages 18–40 · Women only
By country, each count listing its studies:
elagolix: first FDA approval 2018 (ORILISSA). What it is approved for, and how studies give it, is on its page →
Of the 179 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 125 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 49 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 67 across 541 interventional studies indexed under Endometriosis.
Median enrollment 165 across the 22 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 22 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
21 studies in Endometriosis by AbbVie: none open now, 1 under way, 1 of them phase 3. Of 19 finished, 14 (74%) have results posted.
Among the 21 studies in Endometriosis by AbbVie, this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 16th registered.
AbbVie’s Endometriosis studies by the year they started, since 2006.
2 of the studies testing elagolix in Endometriosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375811Phase 3Yale UniversityPre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp | 2027-03-31 |
| NCT04333576Phase 3AbbVieStudy Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing elagolix in Endometriosis, from their registry updates:
Among AbbVie’s 21 in Endometriosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, dose-escalation study designed to evaluate the safety and efficacy of both elagolix alone and elagolix plus estradiol/norethindrone acetate (E2/NETA) over 24 months in the management of endometriosis with associated moderate to severe pain in premenopausal women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant must have the following documented in the e-Diary during the last 35 days prior to Study Day 1:
Exclusion Criteria:
Participant has either
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD Month 4 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 3 and continue treatment through Month 24
Drug: elagolix
Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD Month 4 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24.
Drug: elagolix · Drug: estradiol/norethindrone acetate (E2/NETA)
Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group Month 7 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 6 and assigned to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24.
Drug: elagolix · Drug: estradiol/norethindrone acetate (E2/NETA)
Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group Month 7 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 6 and continue treatment through Month 24.
Drug: elagolix
Tablets
Drug pages: Estradiol · Norethindrone Acetate
Capsules
Proportion of Responders at Month 6 Based on DYS Pain Scale
Proportion of responders at Month 6 based upon the scale for DYS pain scale (ranging from 0 \[none\] to 3 \[severe\]) using the daily e-Diary, as well as no increased analgesic rescue use for endometriosis-associated pain.
Time frame: Month 6
Proportion of Responders at Month 6 Based on NMPP Pain Scale
Proportion of responders at Month 6 based upon the scale for NMPP pain scale (ranging from 0 \[none\] to 3 \[severe\]) using the daily e-Diary, as well as no increased analgesic rescue use for endometriosis-associated pain.
Time frame: Month 6
Change From Baseline in DYS at Month 6
The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
Time frame: Month 0 (baseline), Month 6
Change From Baseline in NMPP at Month 6
The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
Time frame: Month 0 (baseline), Month 6
Change From Baseline in Dyspareunia at Month 6
The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
Time frame: Month 0 (baseline), Month 6
Change From Baseline in Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS) at Month 6
The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
Time frame: Month 0 (baseline), Month 6
Change From Baseline in Rescue Analgesic Use Across Both Classes of Rescue Analgesics (NSAIDs/Opioids) at Month 6
Based on average pill counts and assessed using the daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.
Time frame: Month 0 (baseline), Month 6
Percentage of Participants With 30% or More Reduction From Baseline Based on the 35 Day Mean of the Daily Diary Endometriosis-Associated Pain Score Via NRS at Month 6
The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window.
Time frame: Month 6
Proportion of Responders Over Time
As assessed by change and percent change from baseline in average pain score and rescue analgesic use monthly for DYS, NMPP, dyspareunia, and Daily Diary endometriosis-associated pain score via NRS, respectively.
Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Proportion of Responders Over Time (Not Taking Into Consideration of Analgesic Use)
As assessed by change and percent change from Baseline in average pain score and rescue analgesic use monthly for DYS, NMPP, dyspareunia, and Daily Diary endometriosis-associated pain score via NRS, respectively.
Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Change From Baseline Over Time in Monthly Average DYS Pain Score
The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. The analysis was based on a 28-day window. If a participant prematurely discontinued during the open-label period, based on the analysis window, some data might fall into Month 4 analysis.
Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Change From Baseline Over Time in Monthly Average NMPP Pain Score
The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Change From Baseline Over Time in Monthly Average Dyspareunia Pain Score
The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Change From Baseline Over Time in Monthly Average Daily Diary Endometriosis-Associated Pain Score Via NRS
The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Percent Change From Baseline to Each Month During the Treatment Period for DYS
The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Percent Change From Baseline to Each Month During the Treatment Period for NMPP
The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Percent Change From Baseline to Each Month During the Treatment Period for Dyspareunia
The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Percent Change From Baseline to Each Month During the Treatment Period for Daily Diary Endometriosis-Associated Pain Score Via NRS
The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Change From Baseline Over Time in Daily Rescue Analgesic Use Across Both Classes of Rescue Analgesics
Based on average pill counts and assessed using a daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.
Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Number of Analgesic Use Responders and Non-Responders Over Time
Based only on reduction of rescue analgesics used. Responders were defined as: * participants with no analgesic use at screening and no analgesic use added * participants with NSAID only use at screening and NSAID dose stopped, decreased, or stable (\<15% increase) and no opioid use added * participants with opioid only use at screening and opioid dose stopped, decreased, or stable (\<15% increase), opioid dose stopped and NSAID substituted (any dose), opioid dose decreased and NSAID added (any dose) * participants with NSAID + opioid use at screening and any of the following: NSAID dose stopped + opioid analgesic use stopped, decreased, or stable (\<15% increase); NSAID dose decreased + opioid analgesic use stopped, decreased, or stable (\<15% increase); NSAID dose stable (\< 15% increase) + opioid analgesic use stopped, decreased, or stable (\<15% increase); NSAID dose increased by \>15% + opioid analgesic use stopped; NSAID dose increased by \>15% + opioid analgesic dose decreases.
Time frame: Months 1, 2, 3, 4, 5, 6
Patient Global Impression of Change (PGIC) Scores Over Time
The PGIC is a 7-point response scale where participants rate their endometriosis related pain as: very much improved (1), much improved (2), minimally improved (3), not changed (4), minimally worse (5), much worse (6), very much worse (7).
Time frame: Months 1, 2, 3, 4, 5, 6
Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time
The endometriosis-associated pain questionnaire is an 11-point NRS assessing overall endometriosis-associated pain over a 7-day recall period. Participants assessed their endometriosis-associated pain on a scale of 0 to 10, with 0 = no pain and 10 = worst pain ever.
Time frame: Month 0 (baseline), Months 1, 2, 3, 4, 5, 6
Endometriosis Health Profile-30 (EHP-30) Scores Over Time: Pain
The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.
Time frame: Month 0 (baseline), Months 3, 6
EHP-30 Scores Over Time: Control and Powerlessness
The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.
Time frame: Month 0 (baseline), Months 3, 6
EHP-30 Scores Over Time: Emotional Well-Being
The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.
Time frame: Month 0 (baseline), Months 3, 6
EHP-30 Scores Over Time: Social Support
The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.
Time frame: Month 0 (baseline), Months 3, 6
EHP-30 Scores Over Time: Self-Image
The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.
Time frame: Month 0 (baseline), Months 3, 6
EHP-30 Scores Over Time: Sexual Intercourse
The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.
Time frame: Month 0 (baseline), Months 3, 6
EuroQol-5D 5 Level (EQ-5D-5L) Scores Over Time: Mobility
The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).
Time frame: Month 0 (baseline), Months 3, 6
EQ-5D-5L Scores Over Time: Self-Care
The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).
Time frame: Month 0 (baseline), Months 3, 6
EQ-5D-5L Scores Over Time: Usual Activities
The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).
Time frame: Month 0 (baseline), Months 3, 6
EQ-5D-5L Scores Over Time: Pain/Discomfort
The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).
Time frame: Month 0 (baseline), Months 3, 6
EQ-5D-5L Scores Over Time: Anxiety/Depression
The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).
Time frame: Month 0 (baseline), Months 3, 6
EQ-5D-5L VAS Scores Over Time: Health Today
The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate VAS indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).
Time frame: Month 0 (baseline), Months 3, 6
Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Scores Over Time: Percent Work Missed Due to Problem
Absenteeism is presented as the mean percentage of work time missed due to health problem (as reported on the WPAI:SHP), and is calculated as: 100\*number of hours of work missed due to health problem / (number of hours of work missed due to health problem + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
Time frame: Month 0 (baseline), Month 6
WPAI:SHP Scores Over Time: Percent Impairment While Working Due to Problem
Presenteeism (the extent to which health problem decreased productivity) is presented as the mean percentage of impairment while working due to health problem, and is calculated as: 100\*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI:SHP is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
Time frame: Month 0 (baseline), Month 6
WPAI:SHP Scores Over Time: Percent Overall Work Impairment Due to Problem
The mean percentage of overall work impairment due to health problem (based on the WPAI questionnaire) is presented, and is calculated as: Absenteeism (%) + extent to which health problem decreased productivity (%)\* \[number of hours worked / (number of hours of work missed due to health problem + number of hours worked)\]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
Time frame: Month 0 (baseline), Month 6
WPAI:SHP Scores Over Time: Percent Activity Impairment Due to Problem
Activity impairment due to health problem (the extent to which health problem affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, and is calculated as 100\*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
Time frame: Month 0 (baseline), Month 6
Health Endometriosis Treatment Satisfaction Questionnaire (ETSQ) Scores Over Time
The 6-item ETSQ was developed to assess patient-reported satisfaction with effects on endometriosis pain, dysmenorrhea, dyspareunia, amount of bleeding tolerability and overall treatment satisfaction. The ETSQ has a 7 point response scale. The range for this scale is 0 to 36, with lower ETSQ scores reflecting lower levels of satisfaction with endometriosis treatment.
Time frame: Month 0 (baseline), Months 3, 6
PROMIS Fatigue Short Form 6a Scores Over Time
The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue. Possible scores range from 6 to 30, 6 = not at all (no fatigue), and 30 = very much (most fatigue).
Time frame: Month 0 (baseline), Month 6
| Milestone | Group A | Group B | Group C |
|---|---|---|---|
| Started | 7 | 3 | 1 |
| Completed | 0 | 3 | 1 |
| Not completed | 7 | 0 | 0 |
| Milestone | Group A | Group B | Group C |
|---|---|---|---|
| Started | 0 | 3 | 1 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 3 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 3 | 1 |
Proportion of responders at Month 6 based upon the scale for DYS pain scale (ranging from 0 \[none\] to 3 \[severe\]) using the daily e-Diary, as well as no increased analgesic rescue use for endometriosis-associated pain.
No measurements were reported for this outcome.
Proportion of responders at Month 6 based upon the scale for NMPP pain scale (ranging from 0 \[none\] to 3 \[severe\]) using the daily e-Diary, as well as no increased analgesic rescue use for endometriosis-associated pain.
No measurements were reported for this outcome.
The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Change From Baseline in DYS at Month 6 | — | -0.23 ± NA | — |
The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Change From Baseline in NMPP at Month 6 | — | -0.13 ± 0.061 | — |
The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Change From Baseline in Dyspareunia at Month 6 | — | 0.29 ± NA | — |
The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Change From Baseline in Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS) at Month 6 | — | -1.36 ± 0.020 | — |
Based on average pill counts and assessed using the daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.
| pills/day | Group A | Group B | Group C |
|---|---|---|---|
| NSAID: Change at Month 6 | — | 0.63 ± 0.606 | — |
| Opioid: Change at Month 6 | — | 0.09 ± 0.121 | — |
| NSAID + Opioid: Change at Month 6 | — | 0.71 ± 0.485 | — |
The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window.
| percentage of participants | Group A | Group B | Group C |
|---|---|---|---|
| Percentage of Participants With 30% or More Reduction From Baseline Based on the 35 Day Mean of the Daily Diary Endometriosis-Associated Pain Score Via NRS at Month 6 | — | 50.0 | — |
As assessed by change and percent change from baseline in average pain score and rescue analgesic use monthly for DYS, NMPP, dyspareunia, and Daily Diary endometriosis-associated pain score via NRS, respectively.
No measurements were reported for this outcome.
As assessed by change and percent change from Baseline in average pain score and rescue analgesic use monthly for DYS, NMPP, dyspareunia, and Daily Diary endometriosis-associated pain score via NRS, respectively.
No measurements were reported for this outcome.
The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement. The analysis was based on a 28-day window. If a participant prematurely discontinued during the open-label period, based on the analysis window, some data might fall into Month 4 analysis.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Change at Month 1 | 0.05 ± 0.655 | -0.04 ± NA | — |
| Change at Month 2 | -0.18 ± 0.124 | -0.26 ± NA | — |
| Change at Month 3 | -0.50 ± 0.263 | -0.34 ± NA | — |
| Change at Month 4 | -0.69 ± NA | -0.06 ± NA | — |
| Change at Month 5 | — | -0.16 ± 0.141 | — |
| Change at Month 6 | — | -0.23 ± NA | — |
The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Change at Month 1 | -0.13 ± 0.252 | -0.07 ± 0.508 | 0.39 ± NA |
| Change at Month 2 | -0.48 ± 0.394 | -0.30 ± 0.167 | 0.29 ± NA |
| Change at Month 3 | -0.70 ± 0.828 | -0.30 ± 0.092 | 0.54 ± NA |
| Change at Month 4 | -1.34 ± NA | -0.34 ± 0.029 | 0.46 ± NA |
| Change at Month 5 | — | -0.27 ± 0.256 | — |
| Change at Month 6 | — | -0.13 ± 0.061 | — |
The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Change at Month 1 | -0.50 ± 0.741 | 0.30 ± NA | -0.29 ± NA |
| Change at Month 2 | -1.44 ± 1.071 | 0.06 ± NA | -0.37 ± NA |
| Change at Month 3 | -2.20 ± NA | 0.07 ± 0.101 | -0.03 ± NA |
| Change at Month 4 | -2.23 ± NA | 0.09 ± 0.040 | -0.03 ± NA |
| Change at Month 5 | — | 0.09 ± 0.081 | — |
| Change at Month 6 | — | 0.29 ± NA | — |
The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Change at Month 1 | -0.86 ± 1.975 | -0.89 ± 1.159 | -0.84 ± NA |
| Change at Month 2 | -2.40 ± 2.106 | -2.02 ± 0.758 | -1.40 ± NA |
| Change at Month 3 | -3.70 ± 3.616 | -1.81 ± 0.430 | -1.34 ± NA |
| Change at Month 4 | -6.43 ± NA | -1.43 ± 1.078 | -1.06 ± NA |
| Change at Month 5 | — | -1.40 ± 0.961 | — |
| Change at Month 6 | — | -1.36 ± 0.020 | — |
The DYS pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
| percent change of units on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Percent Change at Month 1 | 1.67 ± 109.961 | -7.89 ± NA | — |
| Percent Change at Month 2 | -27.45 ± 17.119 | -75.00 ± NA | — |
| Percent Change at Month 3 | -62.92 ± 24.159 | -85.71 ± NA | — |
| Percent Change at Month 4 | -80.00 ± NA | -16.67 ± NA | — |
| Percent Change at Month 5 | — | -40.48 ± 33.672 | — |
| Percent Change at Month 6 | — | -57.14 ± NA | — |
The NMPP pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
| percentage change of units on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Percent Change at Month 1 | -11.81 ± 26.677 | 4.22 ± 53.238 | 16.07 ± NA |
| Percent Change at Month 2 | -37.53 ± 31.150 | -34.21 ± 18.044 | 11.90 ± NA |
| Percent Change at Month 3 | -38.26 ± 42.319 | -38.03 ± 20.343 | 22.62 ± NA |
| Percent Change at Month 4 | -71.21 ± NA | -44.49 ± 20.725 | 19.05 ± NA |
| Percent Change at Month 5 | — | -28.40 ± 33.641 | — |
| Percent Change at Month 6 | — | -17.23 ± 16.044 | — |
The dyspareunia pain scale score ranged from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
| percentage change of units on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Percent Change at Month 1 | 0.14 ± 18.180 | -15.27 ± 26.791 | -9.52 ± NA |
| Percent Change at Month 2 | 6.60 ± 15.719 | -15.26 ± 21.840 | -12.38 ± NA |
| Percent Change at Month 3 | 60.88 ± 65.632 | -21.63 ± 24.719 | -0.95 ± NA |
| Percent Change at Month 4 | 106.25 ± NA | -12.67 ± 20.433 | -0.95 ± NA |
| Percent Change at Month 5 | — | -14.86 ± 16.002 | — |
| Percent Change at Month 6 | — | -18.08 ± 25.571 | — |
The NRS for overall endometriosis-associated pain ranges from 0 (none) to 10 (worst pain ever), recorded in a daily eDiary and averaged monthly based on a 35-day window. A negative change from baseline indicates improvement.
| percentage change of score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Percent Change at Month 1 | -14.10 ± 37.146 | -19.61 ± 35.468 | -11.34 ± NA |
| Percent Change at Month 2 | -37.82 ± 18.066 | -56.25 ± 4.507 | -18.99 ± NA |
| Percent Change at Month 3 | -43.98 ± 35.509 | -53.05 ± 13.803 | -18.22 ± NA |
| Percent Change at Month 4 | -70.98 ± NA | -38.00 ± 31.275 | -14.34 ± NA |
| Percent Change at Month 5 | — | -35.81 ± 9.326 | — |
| Percent Change at Month 6 | — | -33.56 ± 11.357 | — |
Based on average pill counts and assessed using a daily e-Diary. Permitted non-steroidal anti-inflammatory drugs (NSAIDs) included naproxen, ibuprofen, diclofenac, and celecoxib. Permitted opioids included hydrocodone + acetaminophen and codeine phosphate + acetaminophen.
| pills/day | Group A | Group B | Group C |
|---|---|---|---|
| NSAID: Change at Month 1 | -0.84 ± 0.796 | 0.09 ± 0.388 | -0.67 ± NA |
| NSAID: Change at Month 2 | -1.15 ± 0.785 | -0.17 ± 0.834 | 0.63 ± NA |
| NSAID: Change at Month 3 | -0.96 ± 1.030 | -0.43 ± 1.091 | -0.71 ± NA |
| NSAID: Change at Month 4 | -1.69 ± NA | 0.01 ± 0.845 | -0.63 ± NA |
| NSAID: Change at Month 5 | — | 0.23 ± 1.197 | — |
| NSAID: Change at Month 6 | — | 0.63 ± 0.606 | — |
| Opioid: Change at Month 1 | 0.12 ± 0.552 | -0.06 ± 0.099 | -0.43 ± NA |
| Opioid: Change at Month 2 | -0.17 ± 0.263 | -0.03 ± 0.049 | -0.51 ± NA |
| Opioid: Change at Month 3 | -0.17 ± 0.242 | 0.02 ± 0.016 | -0.49 ± NA |
| Opioid: Change at Month 4 | -0.34 ± NA | -0.01 ± 0.044 | -0.40 ± NA |
| Opioid: Change at Month 5 | — | -0.05 ± 0.082 | — |
| Opioid: Change at Month 6 | — | 0.09 ± 0.121 | — |
| NSAID + Opioid: Change at Month 1 | -0.72 ± 1.178 | 0.03 ± 0.436 | -1.10 ± NA |
| NSAID + Opioid: Change at Month 2 | -1.33 ± 0.767 | -0.20 ± 0.830 | -1.14 ± NA |
| NSAID + Opioid: Change at Month 3 | -1.13 ± 1.273 | -0.41 ± 1.107 | -1.20 ± NA |
| NSAID + Opioid: Change at Month 4 | -2.03 ± NA | -0.00 ± 0.863 | -1.03 ± NA |
| NSAID + Opioid: Change at Month 5 | — | 0.18 ± 1.217 | — |
| NSAID + Opioid: Change at Month 6 | — | 0.71 ± 0.485 | — |
Based only on reduction of rescue analgesics used. Responders were defined as: * participants with no analgesic use at screening and no analgesic use added * participants with NSAID only use at screening and NSAID dose stopped, decreased, or stable (\<15% increase) and no opioid use added * participants with opioid only use at screening and opioid dose stopped, decreased, or stable (\<15% increase), opioid dose stopped and NSAID substituted (any dose), opioid dose decreased and NSAID added (any dose) * participants with NSAID + opioid use at screening and any of the following: NSAID dose stopped + opioid analgesic use stopped, decreased, or stable (\<15% increase); NSAID dose decreased + opioid analgesic use stopped, decreased, or stable (\<15% increase); NSAID dose stable (\< 15% increase) + opioid analgesic use stopped, decreased, or stable (\<15% increase); NSAID dose increased by \>15% + opioid analgesic use stopped; NSAID dose increased by \>15% + opioid analgesic dose decreases.
| Participants | Group A | Group B | Group C |
|---|---|---|---|
| Month 1: Responder | 5 | 2 | 1 |
| Month 1: Non-Responder | 2 | 1 | 0 |
| Month 2: Responder | 4 | 2 | 1 |
| Month 2: Non-Responder | 1 | 1 | 0 |
| Month 3: Responder | 2 | 1 | 1 |
| Month 3: Non-Responder | 0 | 2 | 0 |
| Month 4: Responder | 1 | 2 | 1 |
| Month 4: Non-Responder | 0 | 1 | 0 |
| Month 5: Responder | 0 | 2 | 0 |
| Month 5: Non-Responder | 0 | 1 | 0 |
| Month 6: Responder | 0 | 0 | 0 |
| Month 6: Non-Responder | 0 | 2 | 0 |
The PGIC is a 7-point response scale where participants rate their endometriosis related pain as: very much improved (1), much improved (2), minimally improved (3), not changed (4), minimally worse (5), much worse (6), very much worse (7).
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Month 1 | 2.9 ± 1.35 | 2.3 ± 0.58 | 2.0 ± NA |
| Month 2 | 2.0 ± 0.00 | 1.3 ± 0.58 | 2.0 ± NA |
| Month 3 | 2.0 ± NA | 2.0 ± 1.00 | 5.0 ± NA |
| Month 4 | — | 2.0 ± 1.00 | 2.0 ± NA |
| Month 5 | — | 2.5 ± 0.71 | — |
| Month 6 | — | 1.0 ± NA | — |
The endometriosis-associated pain questionnaire is an 11-point NRS assessing overall endometriosis-associated pain over a 7-day recall period. Participants assessed their endometriosis-associated pain on a scale of 0 to 10, with 0 = no pain and 10 = worst pain ever.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 8.2 ± 1.79 | 9.0 ± 1.00 | 7.0 ± NA |
| Month 1 | 5.7 ± 3.04 | 7.7 ± 1.15 | 8.0 ± NA |
| Month 2 | 4.5 ± 0.71 | 2.7 ± 1.15 | 5.0 ± NA |
| Month 3 | 9.0 ± NA | 5.3 ± 2.31 | 8.0 ± NA |
| Month 4 | — | 3.3 ± 0.58 | 7.0 ± NA |
| Month 5 | — | 8.0 ± 0.00 | — |
| Month 6 | — | 4.0 ± NA | — |
The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 59.42 ± 11.694 | 47.73 ± 14.193 | 59.09 ± NA |
| Month 3 | 38.07 ± 26.529 | 17.42 ± 22.422 | 38.64 ± NA |
| Month 6 | — | 27.27 ± NA | — |
The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 71.43 ± 19.159 | 56.94 ± 19.691 | 41.67 ± NA |
| Month 3 | 36.46 ± 32.874 | 26.39 ± 21.382 | 25.00 ± NA |
| Month 6 | — | 8.33 ± NA | — |
The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 29.76 ± 8.815 | 50.00 ± 8.333 | 45.83 ± NA |
| Month 3 | 18.75 ± 12.500 | 23.61 ± 17.347 | 37.50 ± NA |
| Month 6 | — | 25.00 ± NA | — |
The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 48.21 ± 21.565 | 45.83 ± 19.094 | 50.00 ± NA |
| Month 3 | 17.19 ± 11.831 | 16.67 ± 28.868 | 18.75 ± NA |
| Month 6 | — | 25.00 ± NA | — |
The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 50.00 ± 22.048 | 36.11 ± 31.549 | 75.00 ± NA |
| Month 3 | 43.75 ± 41.597 | 8.33 ± 14.434 | 8.33 ± NA |
| Month 6 | — | 16.67 ± NA | — |
The EHP-30 is a disease-specific self-administered questionnaire used to measure health-related quality of life in women with endometriosis. Domains used in the study included Pain, Control and Powerlessness, Well-Being, Social Support, Self-Image, and Sexual Intercourse. Each domain is calculated on a scale from 0 = best possible health status to 100 = worst possible health status.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 70.00 ± 22.361 | 62.50 ± 31.820 | 60.00 ± NA |
| Month 3 | 45.00 ± 23.452 | 45.00 ± 42.426 | 60.00 ± NA |
| Month 6 | — | 30.00 ± NA | — |
The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 1.4 ± 0.53 | 1.0 ± 0.00 | 1.0 ± NA |
| Month 3 | 1.3 ± 0.50 | 1.0 ± 0.00 | 2.0 ± NA |
| Month 6 | — | 1.0 ± NA | — |
The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 1.0 ± 0.00 | 1.0 ± 0.00 | 1.0 ± NA |
| Month 3 | 1.0 ± 0.00 | 1.0 ± 0.00 | 1.0 ± NA |
| Month 6 | — | 1.0 ± NA | — |
The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 2.0 ± 0.82 | 1.3 ± 0.58 | 1.0 ± NA |
| Month 3 | 1.5 ± 0.58 | 1.7 ± 1.15 | 2.0 ± NA |
| Month 6 | — | 1.0 ± NA | — |
The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 2.7 ± 0.76 | 2.7 ± 0.58 | 4.0 ± NA |
| Month 3 | 2.0 ± 1.15 | 1.7 ± 0.58 | 3.0 ± NA |
| Month 6 | — | 1.0 ± NA | — |
The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate visual analog scale (VAS) indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 1.0 ± 0.00 | 1.3 ± 0.58 | 1.0 ± NA |
| Month 3 | 1.0 ± 0.00 | 1.0 ± 0.00 | 1.0 ± NA |
| Month 6 | — | 1.0 ± NA | — |
The EQ-5D-5L is a health state utility instrument with 5 items that comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which is rated on 5 levels of severity (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems) and a separate VAS indicating a participant's rating of their current health status (health today) on a scale of from 0 (worst health imaginable) to 100 (best health imaginable).
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 79.7 ± 15.16 | 53.3 ± 35.12 | 72.0 ± NA |
| Month 3 | 72.8 ± 17.63 | 85.0 ± 15.00 | 70.0 ± NA |
| Month 6 | — | 94.0 ± NA | — |
Absenteeism is presented as the mean percentage of work time missed due to health problem (as reported on the WPAI:SHP), and is calculated as: 100\*number of hours of work missed due to health problem / (number of hours of work missed due to health problem + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
| percent of work time missed | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 0.16 ± 0.205 | 0.08 ± 0.144 | — |
| Month 6 | 0.00 ± 0.000 | 0.00 ± NA | — |
Presenteeism (the extent to which health problem decreased productivity) is presented as the mean percentage of impairment while working due to health problem, and is calculated as: 100\*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI:SHP is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
| percent impairment while working | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 0.57 ± 0.273 | 0.53 ± 0.153 | — |
| Month 6 | 0.30 ± 0.265 | 0.30 ± NA | — |
The mean percentage of overall work impairment due to health problem (based on the WPAI questionnaire) is presented, and is calculated as: Absenteeism (%) + extent to which health problem decreased productivity (%)\* \[number of hours worked / (number of hours of work missed due to health problem + number of hours worked)\]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
| percent overall work impairment | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 0.61 ± 0.307 | 0.56 ± 0.194 | — |
| Month 6 | 0.30 ± 0.265 | 0.30 ± NA | — |
Activity impairment due to health problem (the extent to which health problem affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, and is calculated as 100\*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity.
| percentage impairment of activity | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 0.66 ± 0.237 | 0.67 ± 0.058 | 0.70 ± NA |
| Month 6 | 0.40 ± 0.346 | 0.30 ± NA | 0.70 ± NA |
The 6-item ETSQ was developed to assess patient-reported satisfaction with effects on endometriosis pain, dysmenorrhea, dyspareunia, amount of bleeding tolerability and overall treatment satisfaction. The ETSQ has a 7 point response scale. The range for this scale is 0 to 36, with lower ETSQ scores reflecting lower levels of satisfaction with endometriosis treatment.
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 19.71 ± 4.536 | 18.00 ± 0.000 | 18.00 ± NA |
| Month 3 | 22.25 ± 9.430 | 25.47 ± 6.652 | 25.00 ± NA |
| Month 6 | — | 31.00 ± NA | — |
The PROMIS Fatigue Short Form 6a is self-administered and composed of 6 questions to evaluate fatigue. Possible scores range from 6 to 30, 6 = not at all (no fatigue), and 30 = very much (most fatigue).
| score on a scale | Group A | Group B | Group C |
|---|---|---|---|
| Baseline | 22.1 ± 4.10 | 19.3 ± 6.11 | 27.0 ± NA |
| Month 6 | 15.3 ± 7.77 | 11.0 ± NA | 21.0 ± NA |
Collected over From first dose of study drug up to 6 months, plus 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Group B | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Group C | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Group A | Group B | Group C |
|---|---|---|---|
| ANAPHYLACTIC REACTIONImmune system disorders | 0/7 | 0/3 | 1/1 |
| DRUG HYPERSENSITIVITYImmune system disorders | 0/7 | 0/3 | 1/1 |
| GARDNERELLA INFECTIONInfections and infestations | 0/7 | 1/3 | 1/1 |
| PELVIC PAINReproductive system and breast disorders | 0/7 | 1/3 | 1/1 |
| THROAT TIGHTNESSRespiratory, thoracic and mediastinal disorders | 0/7 | 0/3 | 1/1 |
| EAR DISCOMFORTEar and labyrinth disorders | 0/7 | 1/3 | 0/1 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 0/7 | 1/3 | 0/1 |
| DIARRHOEAGastrointestinal disorders | 1/7 | 1/3 | 0/1 |
| ORAL HERPESInfections and infestations | 0/7 | 1/3 | 0/1 |
| ADNEXA UTERI PAINReproductive system and breast disorders | 0/7 | 1/3 | 0/1 |
| Age, Customized(Participants) | Group A | Group B | Group C | Total |
|---|---|---|---|---|
| 20 to < 25 years | 1 | 1 | 0 | 2 |
| 25 to < 30 years | 0 | 1 | 0 | 1 |
| 30 to < 35 years | 1 | 0 | 1 | 2 |
| 35 to < 40 years | 1 | 0 | 0 | 1 |
| 40 to < 45 years | 3 | 1 | 0 | 4 |
| 45 to < 50 years | 1 | 0 | 0 | 1 |
| Sex: Female, Male(Participants) | Group A | Group B | Group C | Total |
|---|---|---|---|---|
| Female | 7 | 3 | 1 | 11 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Group A | Group B | Group C | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 3 |
| Not Hispanic or Latino | 6 | 2 | 0 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group A | Group B | Group C | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 0 | 3 |
| White | 5 | 1 | 0 | 6 |
| More than one race | 0 | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Dysmenorrhea (DYS) Pain Scale(score on a scale) | Group A | Group B | Group C | Total |
|---|---|---|---|---|
| Mean | 0.641 ± 0.1689 | 0.429 ± 0.1030 | 0.600 ± NA | 0.579 ± 0.1696 |
| Non-Menstrual Pelvic Pain (NMPP) Pain Scale(score on a scale) | Group A | Group B | Group C | Total |
|---|---|---|---|---|
| Mean | 1.053 ± 0.4534 | 0.914 ± 0.4721 | 2.400 ± NA | 1.138 ± 0.5893 |
| Dyspareunia Pain Scale(score on a scale) | Group A | Group B | Group C | Total |
|---|---|---|---|---|
| Mean | 0.539 ± 0.9064 | 0.043 ± 0.0202 | 3.000 ± NA | 0.686 ± 1.1187 |
| Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS)(score on a scale) | Group A | Group B | Group C | Total |
|---|---|---|---|---|
| Mean | 5.176 ± 1.9302 | 3.638 ± 1.5692 | 7.371 ± NA | 4.956 ± 1.9663 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Dec 2017 to primary completion in Oct 2018, 9 months.
Results were first posted in Nov 2019, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elagolix